Condition: Lyme Disease · Sponsor: ModernaTX, Inc.
This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.
This description comes directly from the study's public registry record.
Moderna WeCare Team · 1-866-663-3762 · WeCareClinicalTrials@modernatx.com
Always discuss trial participation with your own doctor first.
| Colchester Research Group | Truro, Nova Scotia, Canada | Recruiting |
| Bluewater Clinical Research Group Inc. | Sarnia, Ontario, Canada | Recruiting |
| Stouffville Medical Research Institute Inc. | Stouffville, Ontario, Canada | Recruiting |
| Dr. Anil K. Gupta Medicine Professional Corporation Inc. | Toronto, Ontario, Canada | Recruiting |
| Diex Recherche Inc. - Division Joliette | Joliette, Quebec, Canada | Recruiting |
| Diex Recherche Inc. - Division Sherbrooke | Sherbrooke, Quebec, Canada | Recruiting |
| Diex Recherche Inc. - Division Victoriaville | Victoriaville, Quebec, Canada | Recruiting |
| Diex Recherche Inc. - Division Quebec | Québec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07561294